CPRX - Insider Transaction: David S Tierney Sells $666K Worth Of Catalyst Pharmaceuticals Shares | Benzinga
It was reported on December 14, that David S Tierney, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX) executed a significant insider sell, according to an SEC filing.
What Happened: Tierney's decision to sell 50,000 shares of Catalyst Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value of the sale is $666,250.
The latest update on Friday morning shows Catalyst Pharmaceuticals shares up by 0.07%, trading at $14.5.
All You Need to Know About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Insights: Catalyst Pharmaceuticals
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 79.39% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average ...